EFFECTS OF FAS LIGAND ON TISSUE GRAFT REJECTION

FAS 配体对组织移植排斥的影响

基本信息

  • 批准号:
    6547390
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

This project explores the feasibility of inducing tolerance to tissue allografts and xenografts by engineered expression of fas ligand on tissues for transplantation. We have constructed transgenic mice in which murine fas ligand expression is directed to antigen presenting cells (APC) such as Langerhans cells by cloning into an expression vector containing the MHC class II Ealpha promoter. Four founder lines have been established and each line is being bred, backcrossed and assessed by immunocytochemistry for tissue specific expression of the transgene. Following full characterization and additional backcrossing, tissues from such mice will be transplanted onto allogeneic animals and assessed for graft rejection/ tolerance induction. An additional project involving assessment of regulatory mechanisms in expression of fas-ligand on tumor cells has sprung from our observation that fas-ligand expression on such cells is very sensitive to modulation by the expression of a bacterial phosphotransferase, mediated by a neomycin resistance gene. This aspect is of great interest because of reports that tumor cells may have enhanced survival pertaining to their expression of fas-ligand. Because of the recent findings in which expression of fas ligand on tissues for transplantation was shown to modify rejection responses, we expect that the Agency will receive clinical protocols involving use of this construct for allograft or xenograft rejection for evaluation in the near future. This project will enable the Agency to evaluate, in a scientific manner, the merits of such submissions.
本项目探索诱导组织耐受的可行性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A S ROSENBERG其他文献

A S ROSENBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A S ROSENBERG', 18)}}的其他基金

PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
  • 批准号:
    6161320
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
EFFECTS OF FAS LIGAND ON TISSUE GRAFT REJECTION
FAS 配体对组织移植排斥的影响
  • 批准号:
    2568999
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CELLULAR POPULATIONS MEDIATING SKIN ALLOGRAFT REJECTION
介导皮肤同种异体移植排斥的细胞群
  • 批准号:
    3770383
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOPATHOGENESIS OF LP-BM5 INFECTION-MURINE ACQUIRED IMMUNODEFICIENCY DISEASE
LP-BM5感染鼠获得性免疫缺陷病的免疫发病机制
  • 批准号:
    3770384
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
  • 批准号:
    5200785
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
EFFECTS OF FAS LIGAND ON TISSUE GRAFT REJECTION
FAS 配体对组织移植排斥的影响
  • 批准号:
    6161319
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVI
用于评估 RETROVI 安全性的临床前动物模型
  • 批准号:
    6547391
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
  • 批准号:
    2569000
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOPATHOGENESIS OF LP-BM5 INFECTION-MURINE ACQUIRED IMMUNODEFICIENCY DISEASE
LP-BM5感染鼠获得性免疫缺陷病的免疫发病机制
  • 批准号:
    3748227
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

MHC Class II Antigen Presentation In Melanoma: Impact on Immune Recognition
黑色素瘤中 MHC II 类抗原的呈现:对免疫识别的影响
  • 批准号:
    10674177
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
  • 批准号:
    10618790
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
  • 批准号:
    10392325
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
  • 批准号:
    8360306
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
  • 批准号:
    8167705
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
  • 批准号:
    8131116
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
  • 批准号:
    7321929
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
  • 批准号:
    7673392
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
  • 批准号:
    7483748
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
  • 批准号:
    7907767
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了